Cargando…

Different T-cell and B-cell repertoire elicited by the SARS-CoV-2 inactivated vaccine and S1 subunit vaccine in rhesus macaques

Multiple types of SARS-CoV-2 vaccines have been used worldwide, but summarizing their immunologic efficacy post-vaccination remains challenging. The BCR and TCR sequencing based on single-cell sorting makes it possible to evaluate the vaccine-induced immune responses of B or T cells. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Li, Zuo, Yuanyuan, Liu, Shuying, Li, Bingxiang, Wang, Hongye, Li, Heng, Li, Jing, Chen, Yanli, Sun, Ming, Zheng, Huiwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Coronavirus – Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746386/ https://www.ncbi.nlm.nih.gov/pubmed/36070519 http://dx.doi.org/10.1080/21645515.2022.2118477

Ejemplares similares

Booster vaccination is required to elicit and maintain COVID-19 vaccine-induced immunity in SIV-infected macaques
por: Li, Pingchao, et al.
Publicado: (2023)

A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques
por: Li, Yuzhong, et al.
Publicado: (2021)

Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques
por: Xu, Fang, et al.
Publicado: (2022)

Single B cells reveal the antibody responses of rhesus macaques immunized with an inactivated enterovirus D68 vaccine
por: Zheng, Huiwen, et al.
Publicado: (2020)

Single cell characteristics of patients with vaccine-related adverse reactions following inactivated COVID-19 vaccination
por: Jiang, Manling, et al.
Publicado: (2023)

A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2
por: Wang, Shixia, et al.
Publicado: (2022)

Comparative global B cell receptor repertoire difference induced by SARS-CoV-2 infection or vaccination via single-cell V(D)J sequencing
por: He, Bing, et al.
Publicado: (2022)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
por: Li, Tao, et al.
Publicado: (2023)

Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing
por: Tong, Renyang, et al.
Publicado: (2023)

Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants
por: Zhao, Zhuxiang, et al.
Publicado: (2022)

Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice
por: Li, Xingxing, et al.
Publicado: (2022)

Immunological evaluation of an inactivated SARS-CoV-2 vaccine in rhesus macaques
por: Chen, Hongbo, et al.
Publicado: (2021)

Covid-19 vaccines elicit effective IgG responses in an elderly thymus cancer patient with chemotherapy
por: Koller, Akos, et al.
Publicado: (2023)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses
por: He, Qian, et al.
Publicado: (2022)

Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant
por: Yu, Xiaoling, et al.
Publicado: (2022)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

Impaired antibody response to inactivated COVID-19 vaccines in hospitalized patients with type 2 diabetes
por: Zhou, Xiaoying, et al.
Publicado: (2023)

Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV
por: Wang, Qian, et al.
Publicado: (2022)

Effectiveness of vero cell inactivated vaccine against severe acute respiratory infections (SARI) in Sibu, Malaysia: A retrospective test-negative design
por: Toh, Teck-Hock, et al.
Publicado: (2023)

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines
por: Kyaw, Moe H., et al.
Publicado: (2023)

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
por: Ai, Jingwen, et al.
Publicado: (2022)

Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases
por: Yu, Michael Kwan Leung, et al.
Publicado: (2023)

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants
por: Lam, Joy-Yan, et al.
Publicado: (2022)

Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis
por: Zhang, Xiaoyin, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2023)

Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China
por: Xu, Hongqin, et al.
Publicado: (2023)

A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern
por: Lee, I-Jung, et al.
Publicado: (2022)

Homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: Comment
por: Mungmunpuntipantip, Rujitika, et al.
Publicado: (2023)

Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents
por: Lopez, Pio, et al.
Publicado: (2023)

Inactivated COVID-19 vaccines, HBV and HIV: Correspondence
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Rhesus Macaque B-Cell Responses to an HIV-1 Trimer Vaccine Revealed by Unbiased Longitudinal Repertoire Analysis
por: Dai, Kaifan, et al.
Publicado: (2015)

A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques
por: Lee, Sujin, et al.
Publicado: (2016)

The SARS-CoV-2 inactivated vaccine enhances the broad neutralization against variants in individuals recovered from COVID-19 up to one year
por: Zhang, Zheng, et al.
Publicado: (2022)

Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection
por: Liang, Huang, et al.
Publicado: (2022)

CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
por: Jin, Lairun, et al.
Publicado: (2022)

Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes
por: Li, Leike, et al.
Publicado: (2019)

B cell receptor signatures associated with strong and poor SARS-CoV-2 vaccine responses
por: Lin, Ke, et al.
Publicado: (2022)

A recombinant Mycobacterium smegmatis-based surface display system for developing the T cell-based COVID-19 vaccine
por: Wen, Ziyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g2hgkrv3aa0fb11amp37l62ebg